top of page
Our Mission
Imagine a safer, more convenient, and exceptionally effective treatment for Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema, and Diabetic Retinopathy that requires significantly fewer injections.

At Optigo Bio, we imagined this for you and are making it a reality.
Optigo Bio - Logo Animation-3.gif

The Optigo Bio logo was inspired directly by the novelty of our product. The logo is comprised of a circle that represents the retina, which is at the very core of our therapy. The circle is made up of 12 distinct segments, each of which represents one monthly injection of medication into the eye. Our mission is to reduce the frequency of risky, expensive, and burdensome injections from once every 1 to 3 months to once every 12 months. Of these 12 segments, one is “Dark” blue and the remaining 11 are “Light” blue. The dark blue segment represents our product. A single injection is delivered once a year. A convenient and effective solution for lifetime better vision.

About Optigo Biotherapeutics

Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases, many of which are currently treated by monthly or bimonthly injections of drugs into the eye(s) by a retina specialist. 1

Screen Shot 2022-02-09 at

We believe that by reducing the frequency at which each dose of drug is delivered, we will reduce the inconvenience, discomfort, risk and expense of existing treatments. In doing so, we hope to reduce the number of patients dropping out of their treatment cycles or having to skip doses due to inconvenient timing.

Optigo Bio’s therapies for Age-related Macular Degeneration, Diabetic Retinopathy and Diabetic Macular Edema aim to prevent vision loss from these blinding retinal diseases with far fewer injections into the eye.

Family Visit
Grandmother and Grandchild
Grandma and Grandchild in Embrace
Optigo Bio’s Solution

Optigo Bio is developing a novel treatment which aims to counter the effects of age-related Macular Degeneration, diabetic retinopathy, and other neovascular diseases of the retina and will be designed to be delivered once a year. With all the benefits of anti-angiogenic injections that prevent further Macular Degeneration, and restore vision lost to Macular Degeneration, Optigo Bio’s Macular Degeneration therapy offers unrivaled innovation.

About Optigo
Optigo's Solution

Meet our Purpose-Driven and Seasoned Team

Houman David Hemmati, MD, PhD white background_edited.png

Optigo Bio in the News

May 2021

Diabetic Macular Edema: Diagnosis and Management

By Niki Elyasi, BS, and Houman David Hemmati, MD, PhD 
Edited By: Bennie H. Jeng, MD

April 2019

Comparison of Ophthalmic Medication Prices Between the United States and Australia

By Ravi Parikh, MD, MPH et al.

bottom of page